High upfront costs make it hard for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies in the pipeline. A combination of installment plans and value-based contracting will likely be the wave of the future for gene therapy reimbursement.
Though Promising, Gene Therapies Face Durability And Reimbursement Headwinds
